Trial Profile

An Escalating Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 17 Sep 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Elezanumab (Primary)
Indications Multiple sclerosis
Focus Adverse reactions; Pharmacokinetics
Sponsors AbbVie

Most Recent Events

12 Sep 2022 Results assessing safety, tolerability, pharmacokinetics, and immunogenicity of elezanumab from two clinical studies: SAD and MAD published in the Annals of Neurology
30 Apr 2019 According to the AbbVie media release, data from this trial will be presented at the American Academy of Neurology Annual Meeting 2019.
12 Oct 2018 Results presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com